Executive Director, Cancer Vaccine Engineering

AstraZeneca plc

Kendall Square (MA)

In loco

USD 282.000 - 423.000

Tempo pieno

4 giorni fa
Candidati tra i primi

Una candidatura completa in un minuto

Curriculum e lettera di presentazione personalizzati, pronti da inviare.

Supera i filtri ATS

Descrizione del lavoro

The Executive Director of Cancer Vaccine Neoantigen Engineering at AstraZeneca plc will lead the molecular engineering and construction of a portfolio of cancer vaccines designed to generate broad, potent, and durable anti-tumor cellular immunity.

You will integrate diverse data (genomic, immunopeptidomic, structural, TCR) to establish predictive design principles, optimize antigen designs, and build scalable, AI‑guided workflows across immunology, oncology, and translational science.

Competenze

  • PhD or equivalent in bioinformatics, immunology, oncology, molecular biology, biochemistry or related discipline with 10+ yrs industry experience.
  • Proven experience developing vaccines to target different antigens in various disease settings.
  • Proven experience with generating multiple vaccine constructs and testing to identify optimal design.
  • Experience working in a cross‑functional team to maximize expertise and accelerate success.
  • Experience developing and implementing novel methods to support vaccine development.
  • Experience supporting or leading interdisciplinary vaccine discovery or development programs.
  • Proven experience leading and managing junior colleagues.
  • Proven experience developing and controlling budgets.
  • Excellent written and verbal communication, business analysis, and consultancy skills.

Mansioni

  • Establish a best‑in‑class epitope discovery, validation, and engineering pipeline.
  • Optimize epitope sequence design and create a multi‑antigen architectural design tool.
  • Engineer antigen expression constructs that maximize T cell breadth, clonal expansion, and durability.
  • Create differentiated intellectual property around epitope design and antigen construct architecture.
  • Work with cross‑disciplinary teams to guide iterative antigen design and preclinical evaluation.
  • Establish strategic relationships across the organization and functions.
  • Build group and expertise around the design of vaccine candidates taking into account target antigens and target indications.
  • Create and foster effective relationships with senior and executive stakeholders in Research, Bioprocess Development, Clinical and Translational Medicine and Global Project Teams to ensure alignment across functions.
  • Pioneer AI based strategies to accelerate the pace of innovation at all levels of research.
  • Collaborate and guide the evaluation of novel business development opportunities.
  • Communicate results internally and externally, as well as their associated risks, uncertainties and limitations.
  • Define the training standards for junior colleagues in line with best practices and principles.

Conoscenze

Leadership
Vaccine development
Cross-functional collaboration
Communication skills
Budget management
Business analysis
Consultancy skills

Formazione

PhD or equivalent in relevant field

Descrizione del lavoro

The Executive Director of Cancer Vaccine Neoantigen Engineering at AstraZeneca plc will lead the molecular engineering and construction of a portfolio of cancer vaccines designed to generate broad, potent, and durable anti-tumor cellular immunity.

You will integrate diverse data (genomic, immunopeptidomic, structural, TCR) to establish predictive design principles, optimize antigen designs, and build scalable, AI‑guided workflows across immunology, oncology, and translational science.

Ottieni la revisione del curriculum gratis e riservata.

o trascina qui il file.

Similar jobs

Offerte di lavoro simili che vale la pena confrontare

Director, Cancer Neoantigen Vaccine Engineering — AI-Driven
Director, Cancer Neoantigen Vaccine Engineering — AI-Driven

AstraZeneca • Cambridge (MA)

In loco
USD 282.000 - 423.000
Variable Pay Bonus
Equity-based incentives
Flexible benefits program
+2
Executive Director, Cancer Vaccine Neoantigen Engineering - Early Infectious Disease
Executive Director, Cancer Vaccine Neoantigen Engineering - Early Infectious Disease

AstraZeneca plc • Kendall Square (MA)

In loco
USD 282.000 - 423.000
Executive Director, Cancer Vaccine Neoantigen Engineering — Early Infectious Disease
Executive Director, Cancer Vaccine Neoantigen Engineering — Early Infectious Disease

AstraZeneca • Cambridge (MA)

In loco
USD 282.000 - 423.000
Variable Pay Bonus
Equity-based incentives
Flexible benefits program
+2
Head of Cancer Vaccine Development & Strategy
Head of Cancer Vaccine Development & Strategy

Glaxosmithkline • Upper Providence

In loco
USD 341.000 - 568.000
Senior Scientist, Oncology Targeted Discovery & ADCs
Senior Scientist, Oncology Targeted Discovery & ADCs

AstraZeneca plc • Cambridge (MA)

Ibrido
USD 119.000 - 178.000
Equity-based incentives
Short-term incentive bonuses
Retirement programs
Director, GenAI Oncology Products & Enterprise AI
Director, GenAI Oncology Products & Enterprise AI

AstraZeneca plc • Gaithersburg (MD)

In loco
USD 186.000 - 279.000
Senior Director, Oncology Competitive Intelligence & Strategy
Senior Director, Oncology Competitive Intelligence & Strategy

AstraZeneca plc • Gaithersburg (MD)

In loco
USD 218.000 - 327.000
Short-term incentives
Equity-based awards
Commissions
+3
Immunology Clinical Science Exec - Senior Group Director
Immunology Clinical Science Exec - Senior Group Director

AstraZeneca plc • Kendall Square (MA)

In loco
USD 260.000 - 350.000
Director, Oncology Research — T-Cell Engager Leadership
Director, Oncology Research — T-Cell Engager Leadership

Amgen Inc. • South San Francisco (CA)

In loco
USD 210.000 - 260.000
Total Rewards Plan
Stock-based incentives
Flexible work models
+1
Senior Director, Competitive Intelligence, Oncology R&D
Senior Director, Competitive Intelligence, Oncology R&D

AstraZeneca plc • Boston (MA), Cambridge (MA), Gaithersburg (MD), New York (NY)

Ibrido
GBP 165.000 - 248.000
Equity-based awards
Short-term incentive bonuses
Retirement programs
+1